University of Montana



KEITH KROM PARKER

Associate Professor of Pharmacology and Toxicology

College of Health Professions and Biomedical Sciences

Skaggs School of Pharmacy

Department of Biomedical and Pharmaceutical Sciences (BMED)

Center for Structural and Functional Neuroscience (CSFN)

The University of Montana

Missoula, Montana 59812-1552

406-243-4235; 406-243-6498; keith.parker@umontana.edu

Professional Summary: Neuropharmacologist; Neurochemist; primary basic research interests in serotonin receptor systems; primary applied research interest in development of superior anti-migraine drugs; research methodologies focusing on neural cell culture systems in association with molecular biological techniques; receptor binding assays and signal transduction systems.

Employment History:

University of Montana: 1-1-93 to present.

Western Montana College: 8-1-81 to 12-31-92; Assist., Assoc., and Full Professor of Chemistry; Dean of Faculty, 4/1/89-12/31/92.

University of Denver: 11-1-79 to 6-30-81; Research Associate, Department of Chemistry; laboratory of Dr. Eric Wickstrom.

University of Colorado Health Sciences Center, Denver: 10-1-77 to 9-30-79; Post-doctoral Fellow, Department of Pharmacology; laboratory of Dr. Antonia Vernadakis.

Education:

University of California, San Francisco: Ph.D., September 1977; Department of Pharmacology and Toxicology; laboratory of Dr. Anthony Trevor.

Montana State University, Bozeman, MT: B.S., March 1972; Department of Psychology.

Scientific Societies (Past and Present Memberships):

American Association for the Advancement of Science

American Chemical Society

American Society of Pharmacognosy

Montana Academy of Sciences

Sigma Xi: The Scientific Research Society

Society for Neuroscience

Western Pharmacology Society

Funding History:

American Cancer Society Institutional Grant (MSU): "Regulation of Differentiation in C-6 Glioma." $4,200; 1989-1990.

University of Montana Grants Program (UM): "Retinoblastoma as a Potential Drug Screening System." $2,200; 1993.

NSF EPSCoR: "Molecular Pharmacology of the 5HT1a Receptor." $82,071; 1993-1996. (E. Dratz, P.I. of the parent grant; MSU)

American Gloxinia & Gesneriad Society: “Migraine Remedies from South American Plants.” $1,500; 1996-1997. (With E. Russo & R. Medora)

Multidisciplinary Assoc. for Psychedelic Studies: “Migraine Remedies from Psychoactive Plants.” $2,500; 1996-1997. (With E. Russo & R. Medora)

NIH AREA: "Peptide Probes of the 5HT1a Receptor-G Protein Interface." $75,000; 1996-1999.

NIH Minority Student (Marvin Devereaux) Supplement:

$6,443: 1997-1998; $6,443: 1998-1999; total: $12,886.

NIH AREA: “Peptide Probes of the 5HT1a Receptor-G Protein Interface.” $75,000; 1999-2002.

NIH COBRE: “Structural Elucidation of the 5HT1a Receptor-G

Protein Interface.” $110,614/year; 2000-2004.

Honors:

American Men and Women in Science (1982-present)

Special Service Award: Montana Federation of Teachers (1987;1989)

Mershon Award: Montana Academy of Sciences, 2001.

Professional Service:

Chairperson, Montana Section, American Chemical Society (1992-93); Treasurer (1987-1991).

Member, Focus Group on Biotechnology: Montana Science and Technology Plan (1992).

President, U. of Montana Chapter: Sigma Xi, The Scientific Research Society (1996-1997).

President, Montana Academy of Sciences (1988-1989); Sectional Vice-President, Pharm. and Tox. Sci. (1984-1987; 2003-2004); Treasurer (2006-2010).

Board of Directors, Western Montana College Foundation (1986-1989).

President, Western Montana College Fac. Assoc. (1983-1987).

Board of Directors, Murdoch Molecular Biology Facility, U. of Montana (1998-2002)

Peer Review (ad hoc): Science; Neurochemical Research; Developmental Neuroscience; International Journal of Developmental Neuroscience; Journal of Neuroscience Research; Molecular and Cellular Biology; Journal of Spinal Cord Medicine; Journal of Cerebral Blood Flow and Metabolism; U.S. Department of Defense; Neurochemistry International; Journal of Neuroscience; Life Sciences; Recent Patents on CNS Drug Discovery; J. Neurochem; Central Nervous System Agents in Medicinal Chemistry; J. Proteomics and Bioinformation; Journal of Nutrition, Health, and Aging.

Member, Editorial Board, J. of Thermodynamics and Catalysis

Member, Editorial Board, Data Set Papers in Pharmacology

Consultant: Mylan Laboratories

Member, Collective Bargaining Team; U. Fac. Assoc., 2010-2012.

Member, Executive Board; U. Fac. Assoc., 2015-2017.

Outside Reviewer: Tenure Application from the U. of Colorado, 2011; 2014; Texas A & M College of Pharmacy, 2015.

External Examiner: Ph.D. Thesis; Annamalai University; India; Summer 2016.

Presentations:

April 2018: At WWAMI History of Medicine Conference, MSU, Bozeman, Montana. “Pharmacology of Opioids in Historical Perspective.”

February, June, September, and December 2014; February, June, September and December, 2015; February, June, September, and December 2016; March, June, and December 2017; March, June 2018. Radiation Safety Training; University of Montana.

April 2013: CSFN Research Seminar Series, University of Montana. “A Small Library of 5HT1a Receptor Ligands.”

February 2012: School of Pharmacy, University of Montana. “Migraine Headache: Cardiovascular Disease.”

February 2011: School of Pharmacy, University of Southern California. “Peptide and Non-Peptide Interactions at the Human 5HT1a Receptor.”

March 2008: University of Catania; Sicily. “Exploring the Human 5HT1a Receptor-G Protein Interface.”

March 2008: University of Catania; Sicily. “Synthetic and Natural Product Probes of the Human 5HT1a Receptor.”

May 2007: In Service to U. of Montana Psychology Faculty and Graduate Students. “A Review of Psychotropic Drugs.”

October 2006: Brain and Learning Conference, Great Falls, MT. “The Neurobiology of Depression: Affective Disorders.”

October 2006: Brain and Learning Conference, Great Falls, MT. “Window on the Human Brain: Portal to the Future.”

June 2004: Montana Neuroscience Retreat, Seeley Lake, MT. “Serotonin Receptors: Future Studies.”

February 2004: Recent Advances in Clinical Medicine, School of Pharmacy and Allied Health Sciences, The University of Montana. “The Pathophysiology and Neurobiology of Pain.”

October 2003: Montana Neuroscience Institute Foundation Public Lecture Series, St. Patrick Hospital and Health Sciences Center, Missoula, MT. “Oh What a Headache: Unraveling the Complexities of Migraine.”

June 2003: Montana Neuroscience Retreat, Seeley Lake, MT. “5HT1a Receptor Intracellular Loop-G Protein Interactions.”

December 2002: Supply Side West, Las Vegas, NV. “The Promise of Promilin.” (With Jerry R. Smith and Dick Hynson)

October 2002: Western Montana College of the University of Montana, Dillon, MT. “Drugs and the Nervous System.”

June 2002: Montana Neuroscience Retreat, Seeley Lake, MT.

“5HT1a Receptor Intracellular Loop-G Protein Interactions.”

June 2001: 56th Northwest Regional Meeting of the American

Chemical Society, Seattle, WA.”Coupling and Activation at the Human 5HT1a Receptor-G Protein Interface.”

December 2000: Division of Biological Sciences, U.M. “A Model of the Human 5HT1a Receptor-G Protein Interface.”

May 2000: 2nd Annual Montana Neuroscience Conference, Salmon

Lake. “A Model of the Human 5HT1a Receptor-G Protein

Interface.”

October 1997: Dept. of Pharm., Toxicol, and Therap., U. of Kansas Medical Center. "The 5HT1a Receptor-G Protein Interface."

August 1997: Dept. of Biol., and Program for Neurosciences, U. of Utah. "The 5HT1a Receptor-G Protein Interface."

March 1997: Dept. of Pharm. Sci., U.M. "The 5HT1a Receptor-G Protein Interface."

April 1996: Research Colloquium, Western Montana College of the University of Montana. "What a Headache: The Development of Anti-Migraine Drugs."

November 1995: Dept. of Chemistry, U.M. "Molecular Pharmacology of 5HT1a and 5HT2a Receptors."

April 1995: Dept. of Chem. and Biochem., M.S.U. "Serotonin Receptor Subtypes as Anti-Migraine Drug Targets."

March 1995: Western Montana Clinic, Polson. "Recent Developments in the Pharmacotherapy of Migraine Headache."

February 1995: Dept. of Pharm. Sci., U.M. "Molecular Pharmacology of 5HT1a Receptors."

July 1994: Canyon Ferry Limnological Institute, Helena. "Perspectives in Neuropharmacological Research."

April 1993: Sigma Xi Seminar Series, U.M. "The Search for Anti-Migraine Drugs from Natural Products."

April 1992: Dept. of Pharm. Sci., U.M. "Ornithine Decarboxylase Activity in Primary Neural Cell Culture."

October 1989: Dept. of Chem., Montana Tech. "Regulation of Differentiation in C6 Glioma."

February 1988: Dept. of History and Philosophy, Montana State University. “New Concepts in Chemical and Biological Warfare.”

March 1987: Dept. of History and Philosophy, Montana State University. “Recent Trends in Chemical and Biological Warfare.”

May 1986: St. Peters Hospital, Helena. "Recent Trends in Neuropharmacology."

February 1986: Dept. of History and Philosophy, Montana State University. “Understanding the Basics in the Development of Chemical and Biological Warfare.”

February 1985: Regional Conference for Mental Health Professionals, Great Falls, Mt. Basic Pharmacology Related to Psychiatric Disorders.”

February 1984: Dept. of History and Philosophy, Montana State University. “The Nature of Chemical and Biological Warfare in the 20th Century.”

December 1983: Dept. of Chem., U.M. "Molecular Rulers for Ribosomes: Studies with Chlorambucil Modified Transfer RNA."

March 1983: Dept. of Chem., Montana Tech. "Molecular Rulers for Ribosomes: Studies with Chlorambucil Modifified Transfer RNA."

October 1982: Dept. of Chem., M.S.U. "Molecular Rulers for Ribosomes: Studies with Chlorambucil Modified Transfer RNA."

April 1981: Dept. of Biol., U. of Denver. “Transdifferentiation of C6 Glioma Cells in Culture.”

March 1981: School of Pharmacy, Washington State U. "Transdifferentiation of C6 Glioma Cells in Culture."

February 1981: U. of South Dakota School of Med. "Molecular Rulers for Ribosomes: Studies with Chlorambucil Modified Transfer RNA."

February 1980: U. of South Dakota School of Med. "Stimulation of Ornithine Decarboxylase Activity in Neural Cell Culture."

February 1979: U. of Colo. Hlth. Sci. Center. "Stimulation of Ornithine Decarboxylase Activity in Neural Cell Culture."

January 1979: Winter Conference on Brain Research, Sun Valley, ID. “Neuropharmacology of Anti-Convulsant Drugs.”

September 1977: UCSF. "Active Site Studies with Native Forms of Electric Eel Acetylcholinesterase."

Invited Meetings:

January 1994: Gordon Conference, Oxnard CA: "Pineal Cell Biology."

August 1989: 35th Gen. Assembly of IUPAC, Lund, Sweden. Corresponding Member of the Commission on Toxicology.

August 1987: 34sth Gen. Assembly of IUPAC, Boston, MA. Corresponding Member of the Commission on Toxicology.

Publications:

Alfonsino, G.E., Santagati, A., Basile, L., Novellino, E., Gaul, C., Squires, C., Braden, M., Gerdes, J. M., Silanes, S.P., Guiccione, S., and Parker, K.K. 5HT1a Binding Affinities of a Series of Serotonin Transporter (SERT) Inhibitors and Related Thermodynamic Insights. Journal of Advances in Medical and Pharmaceutical Sciences 4(1): pgs. 1-12, 2015. Article No. JAMPS.18917. DOI:10.9734/JAMPS/2015/18917.

Hall, B., Squires, C., and Parker, K.K. “Intracellular Loop Peptides of the Human 5HT1a Receptor are Differential Activators of Gi.” Int. J. Peptides, Vol.2012, Article ID 490734. doi:10.1155/2012/490734.

Hall, B., Burnett, A., Christians, A., Halley, C., Goldstein, E., Thiagaraj, H.V., and Parker, K.K. “Thermodynamics of Peptide and Non-Peptide Interactions with the Human 5HT1a Receptor.” Pharmacology 86 (1): 6-14, 2010.

Nieh, M.T., and Parker, K.K. "Spearmint (MENTHA SPICATA, LAMIACEAE) As a Potential Antimigraine Remedy: A Personal Anecdote." J. Alt. Compl. Med. 13 (10): 1161-1162, 2007.

Thiagaraj, H.V., Ortiz, T.C., Devereaux, M.C. Jr., Seaver, B., Hall, B., and Parker, K.K. “Regulation of G Proteins by Human 5-HT1a Receptor TM3/i2 and TM5/i3 Loop Peptides.” Neurochemistry International 50: 109-118, 2007.

Russo, E.B., Burnett, A., Hall, B., and Parker, K.K. “Agonistic Properties of Cannabidiol at 5-HT1A Receptors.” Neurochem. Res. 30 (8): 1037-1043, 2005.

Smith, J.R., Thiagaraj, H.V., Seaver, B., and Parker, K.K. “Differential Activity of Lipoic Acid Enantiomers in Cell Culture.” J. Herbal Pharmacoth. 5 (3): 43-54, 2005.

Thiagaraj, H.V., Thompson, C.M., Russo, E.B., Burnett, A., Goldstein, E., and Parker, K.K. “Binding Properties of Dipropyltryptamine at the Human 5HT1a Receptor.” Pharmacology 74: 193-199, 2005.

Stierle, A.A., Stierle, D.B., Goldstein, E., Parker, K., Bugni, T., Baarson, C., Gress, J., and Blake, D. “A Novel 5-HT Receptor Ligand and Related Cytotoxic Compounds from an Acid Mine Waste Extremophile.” J. Nat. Prods. 66 (8): 1097-1100, 2003.

Thiagaraj, H.V., Ortiz, T.C., Burnett, A., and Parker, K.K. “G Protein Coupling and Activation Characteristics of Intracellular Loops 2 and 3 of the 5HT1a Receptor.” Trends in Comp. Biochem. and Physiol. 9: 117-129,2002.

Ortiz, T.C., Devereaux, M.C., and Parker, K.K. “Structural Variants of a Human 5HT1a Receptor Intracellular Loop 3 Peptide.” Pharmacology 60: 195-202, 2000.

Hayataka, K., O'Connor, M.-F., Kinzler, N., Weber, J.T., and Parker, K.K. "A Bioactive Peptide from the Transmembrane5/Intracellular Loop 3 Region of the Human 5HT1a Receptor." Biochem. Cell Biol. 76(4): 657-660, 1998.

Weber, J.T., Hayataka, K., O'Connor, M.-F., and Parker, K.K. "Rabbit Cerebral Cortex 5HT1a Receptors." Comp. Biochem. Physiol. 117C: 19-24, 1997.

Weber, J.T., O'Connor, M.-F., Hayataka, K., Colson, N., Medora, R., Russo, E.B., and Parker, K.K. "Activity of Parthenolide at 5HT2a Receptors." J. Nat. Prods. 60: 651-654, 1997.

Russo, E.B., Medora, R., Parker, K., and Thompson, C. “An Investigation of Psychedelic Plants and Compounds for Activity in Serotonin Receptor Assays for Headache Treatment and Prophylaxis.” MAPS 7 (1): 4-8, 1996.

Anders, P., Dahy, N., Kieckbusch, J., Passuccio, L., and Parker, K. “A Mini-Review of the Pharmacology and Toxicology of Cocaine.” Proc. of the Montana Academy of Sciences 50: 97-107, 1990.

Parker, K., et al. "A mini-review of the Pharmacology and Toxicology of Marijuana." Proceedings of the Montana Academy of Sciences, 47: 89-97, 1987.

Vernadakis, A., Sakellaridis, N., Mangoura, A., Davies, D. and Parker, K. "Cellular and Molecular Aspects of Glial Cells with Aging." Advances in the Biosciences 61: 371-379, 1986.

Parker, K., Carlin, R., Griffen, W., Kelley, D., Konen, J.,Miller, C., and Williams, L. "A Review of the Pharmacological, Societal, and Therapeutic Aspects of Phencyclidine Use." Proceedings of the Montana Academy of Sciences, 44: 45-51, 1984.

Parker, K., and Wickstrom, E. "Identification of ribosomal proteins and RNA's alkylated by chlorambucilylpentaproyl-3H- phenylalanyl-tRNA." Nucleic Acids Research, 11: 515-524, 1983.

Vernadakis, P., Parker, K., Arnold, E.B., and Norenberg, M.D. "Role of Glial Cells in CNS Aging." In The Aging Brain: Cellular and Molecular Mechanisms of Aging in the Nervous System, Raven Press, New York, 1982.

Wickstrom, E., Parker, K., Hursh, D.A., and Newton, R.L. "Chlorambucilyl 3H Phenylalanyl-tRNA crosslinking to 50s ribosomal subunit proteins L4, L18-20, and L26-27." FEBS Letters, 123: 273-276. 1981.

Vernadakis, A., Parker, K., and Norenberg, M. “Changes in Biochemical Properties of Glial Cells in Culture: In Vitro Differentiation.” In Tissue Culture in Neurobiology(E.Giacobini et al., Eds.). Raven Press, New York, 1980.

Vernadakis, A., and Parker, K. "Drugs and the Developing central nervous system." Pharmacology and Therapeutics, 11:593-647, 1980.

Parker, K., and Vernadakis, A. "Stimulation of Ornithine Decarboxylase Activity in Neural Cell Culture: Potential Role of Insulin." J. Neurochem. 35: 155-163, 1980.

Parker, K.K., Norenberg, M.D., and Vernadakis, A. "Transdifferentiation of C-6 Glial Cells in Culture." Science 208: 179-181, 1980.

Parker, K.K., and Trevor, A.J. “Active Site Stoichiometry Of Native Forms of Eel Acetylcholinesterase.” Proc. West. Pharmacol. Soc. 21: 221-222, 1978.

Parker, K.K., Chan, S.L., and Trevor, A.J. "Purification of the Native Forms of Acetylcholinesterase: Active Site Determination." Arch. Biochem. Biophys. 187: 322-327, 1978.

Trevor, A.J., Gordon, M.A., Parker, K.K., and Chan, S.L. "Acetylcholinesterases." Life Sci. 23: 1209-1220, 1978.

Greenberg, A.G., Parker, K.K., and Trevor, A.J. "Immunochemical Studies of Mammalian Brain Acetylcholinesterase." J. Neurochem. 29: 911-917, 1977.

Abstracts:

Basile, L., Guccione, S., Squires, C., Gaul, C., and Parker, K.K. “Insights Into the Thermodynamic Properties of a 5HT1a Receptor Ligand.” GLISTEN (GPCR-Ligand Interactions, Structures, and Transmembrane Signalling-A European Research Network) Conference, Budapest, Hungary, P410, pg. 72; October, 2014.

Guccione, S., Basile, L., Squires, C., Gaul, C., and Parker, K.K. “Thermodynamic Properties of a 5HT1a Receptor Ligand.” 69th Northwest Regional Meeting of the American Chemical Society (NORM). No. 81, pg. 24, 2014.

Parker, K.K., Hall, B., Rama Rao, K.V., Jayakumar, A.R., Panickar, K.S., and Norenberg, M.D. “Serotonin Receptors in Differentiated Primary Rat Brain Astrocyte Culture.” Soc. Neurosci. Absts. 38: 340.16, 2011.

Villarreal-Calderon, R., Palacios-Moreno, J., Parker, K., and Calderon-Garciduenas, L.“Geneinflammatory expression profiling in right versus left ventricles in young urbanites: what is the long-term impact of myocardial inflammation in the setting of air pollution?”Experimental Biology: 1029.1, 2010

| |

Guccione, S., and Parker, K.K. “Activity of a Series of SERT Inhibitors at the Human 5HT1a Receptor in Culture.” Ann. Meeting of the Montana Academy of Sciences, April 2009.

Hall, B., Squires, C., and Parker, K.K. “Thermodynamics of Human 5HT1a Receptor Loop 2 Peptides.” Soc. for Neurosci. Absts. 33: 465.8, 2007.

Nieh, M.T., and Parker, K.K. “A Personal Anecdote with

Spearmint (Mentha spicata) as Migraine Prophylaxis.” Am. Soc. Pharmacog. Absts. 48: 2007.

Hall, B., Squires, C., Burgstrom, J., and Parker, K.K. q “Human 5HT1a Receptor Loop 2 TM4: Structure-Activity.” American Indians in Science and Engineering Society National Conference, Detroit, MI, 2006.

Hall, B., Madden, L., and Parker, K.K. “Cell Volume Regulation By the Human 5HT1a Receptor.” Scientific Res. Soc. Absts., PR-04, 2006

Hall, B., Squires, C., Burgstrom, J., and Parker, K.K. “Human 5HT1a Receptor Loop 2 TM4: Structure-Activity.” Soc. for Neurosci. Absts. 32: 33.14/C6, 2006.

Hall, B., Christians, A., Parker, L.A., and Parker, K.K. “Loop 2 of the 5HT1a Receptor: Coupling and Activation.” Soc. for Neurosci. Absts. 31: 373.10, 2005.

Hall, B., Burnett, A., Halley, C., Christians, A., Parker, L.A., Medora, R., and Parker, K.K. “Pharmacology of Bacopa at 5HT1a and 5HT2a Receptors.” Am. Soc. of Pharmacog. Absts. 46: P:85, 2005.

Russo, E.B., Burnett, A., Hall, B., Christians, A., Halley, C., Parker, L.A., and Parker, K.K. “Differential Activity of Cannabidiol and Tetrahydrocannabinol at 5HT1a Receptors.” Int. Cannabinoid Res.Soc. Absts. 49: 2005.

Seaver, B., Smith, J. and Parker, K. “The Insulinogenic Potential of Fenugreek and Lipoic Acid Enantiomers in Glucose Sensing HIT-T15 Immortalized Beta Cells.” National Conference on Undergraduate Research (NCUR): Indianapolis, IN, 2004.

Burnett, A., Hall, B., Christians, A., Halley, C., Parker, L.A., and Parker, K.K. “Intracellular Loop Peptide Libraries for the 5HT1a Receptor.” Soc. for Neurosci. Absts. 30: 394.14, 2004.

Hall, B., Burnett, A., Christians, A., Halley, C., Parker, L., Russo, E., and Parker, K.K. “Pharmacology of Cannabidiol at Serotonin Receptors.” Proc. West. Pharmacol. Soc. 47: 43 (M-24), 2004.

Burnett, A., Goldstein, E., Hall, B., Christians, A., and Parker, K.K. “Binding Thermodynamics of Human 5HT1a Receptor Ligands.” Soc. for Neurosci. Absts, 29: 362.18, 2003.

Thiagaraj, H.V., Burnett, A., Hall, B., Seaver, B., Sakaske, S., and Parker, K.K. “A 5HT1a Receptor Peptide Regulates GTP Incorporation into Gi.” Soc. for Neurosci. Absts. 28: 741.5, 2002.

Smith, J.R., Thiagaraj, H.V., and Parker, K.K. “Differential Activity of Lipoic Acid Enantiomers in Cell Culture.” XIV World Congress of Pharmacology (IUPHAR) Absts., 109.6, 2002.

Russo, E., Ben-Shabat, S., Fride, E., Parker, K., and Mechoulam, R. “In Search of Plants, Other than Cannabis Sativa, With Cannabinoid Activity.” Int. Cannabinoid Res. Soc. Absts. 46: 2002.

Thiagaraj, H.V., Ortiz, T., and Parker, K. “Coupling and Activation at the Human 5HT1a Receptor-G Protein Interface.” Am. Chem. Soc. NW Reg.56: 159, 2001.

Thiagaraj, H.V., Russo, E.B., Thompson, C.M., and Parker, K.K.“Pharmacology of Dipropyltryptamine at Human 5HT1a Receptors.” Soc. for Neurosci. Absts. 27: 266.7, 2001.

Ortiz, T.C., Devereaux, M.C., Thiagaraj, H.V., and Parker, K.K. “A Model of the Human 5HT1a Receptor/G Protein Interface.” Presented at Soc. for Neurosci. Satellite Meeting, Serotonin: From the Molecule to the Clinic; New Orleans, LA, November 2000, #156.

Thiagaraj, H.V., Todd, C.L., Seaver, B.P., and Parker, K.K.“Kinetic Properties of Human 5HT1a Receptor Intracellular Loop Peptides.” Soc. for Neurosci. Absts. 26: 47.14, 2000.

Russo, E.B., Macarah, C.M., Thiagaraj, H.V., Medora, R.S., and Parker, K.K. “Activity of the Essential Oil of Hemp at 5HT1a and 5HT2a Receptors.” Am. Soc.Pharmacog. Absts. 41: P174, 2000.

Ortiz, T.C., Devereaux, M.C., and Parker, K.K. “Coupling and G Protein Activating Characteristics of a Human 5-HT1a Receptor i2 Loop Pepide.” Soc. for Neurosci. Absts. 25: 1466, 1999.

Bessac, B.F., Selvage, D.J., Ortiz, T.C., Parker, K.K., and Johnston, C.A. “Immunocytochemical Detection of Mineralocorticoid Receptor in Rat Arcuate Nucleus, But Not Hippocampus.” Proc. West. Pharm. Soc. 42: 138, 1999.

Ortiz, T.C., Devereaux, M.C., and Parker, K.K. “Differential Coupling and G Protein Activating Properties of Human 5-HT1a Receptor I3 Loop Peptides.” Soc. for Neurosci. Absts. 24: 1096, 1998.

Ortiz, T.C., Parker, K.K., and Eyer, C.E. "Differential Activation of C6 Glioma Protein Kinase C Isoforms by a Phorbol Ester and Trimethyltin." Proc. West. Pharmacol. Soc. 40: 155, 1997.

Ortiz, T.C., Hayataka, K., Braun, P., and Parker, K.K. "Structure-Activity Relationships at the Human 5HT1a Receptor/G Protein Interface." Soc. for Neurosci. Absts. 23: 128, 1997.

Parker, K.K., Colson, N., O'Connor, M.-F., Hayataka, K., and Iverson, J. "Peptide Mediated Uncoupling of the Human 5HT1a Receptor." Soc. for Neurosci. Absts. 22: 1324, 1996.

Colson, N., Hayataka, K., Weber, J., Russo, E., Medora, R., and Parker, K.K. "Comparative Pharmacology of Parthenolide at Serotonin Receptors." Am. Soc. Pharmacog. Absts. 37: P123, 1996.

Weber, J.T., Hayataka, K., and Parker, K.K. "Pharmacological Activity of Solubilized Human 5HT1a Receptors." Soc. for Neurosci. Absts. 21: 1854, 1995.

Weber, J., O'Connor, M.-F., and Parker, K. "Characterization of 5HT1a Receptors from Rabbit Brain." Proc. West. Pharmacol. Soc. 38:, 1995.

Weber, J., Morlan, M., and Parker, K.K. "Potential of Y79 Retinoblastoma as a Model Drug Screening System." Proc. Mont. Acad. Sci. 54:, 1994.

Smart, J., Rouse, C., Agrawal, D., and Parker, K.K. "Peptide Growth Factors as Modulators of Differentiation in Glioma." Proc. Mont. Acad. Sci. 53: 52, 1993.

Eyer, C.L., James, W., Manson, R., Smith, J.R., and Parker, K.K. "Determination of Glutamine Synthetase and Catalase Activity in Late Passage C6 Glioma Cell Line." Proc. West. Pharmacol. Soc. 35: 244, 1992.

Smart, J., Alexander, K., Parker,J., and Parker, K. "Clonal and Environmental Factors in Transdifferentiation of C6 Glioma." Proc. Mont. Acad. Sci. 51: 44, 1991.

Parker, K.K. "Regulation of Differentiation in C6 Glioma." Proc. Mont. Acad. Sci. 49: 168, 1989.

Parker, J.A., and Parker, K.K. "New Approaches to Anti-Migraine Drugs: Pharmacognosy of Native American Medicinal Plants." Am. Assoc. Adv. Sci., Jan. 1989.

Parker, J.A., and Parker, K.K. "Pharmacognosy of Southwestern Montana: Search for Migraine-Active Agents." Am. Soc. Pharmacog. Absts. 27: , 1986.

Parker, K.K., and Trevor, A.J. "Structure-Activity Relationships of Acetylcholinesterase Inhibitors." Proc. Mont. Acad. Sci. 45: 129, 1985.

Parker, K.K., and Wickstrom, E. “Structural Analysis of Ribosomes with Oligoproline Molecular Rulers.”Proc. Mont. Acad. Sci. 42: 49, 1983.

Parker, K., Norenberg, M., and Vernadakis, A. "Effect of Cortisol and cAMP on Glutamine Synthetase Activity." Trans. Am. Soc. Neurochem. 11: 101, 1980.

Vernadakis, A., Norenberg, M., and Parker, K. "Differential Glial Expression in Young and Old Passages of C-6 Glial Cells." Int. Soc. Neurochem., Jerusalem, September 1979.

Parker, K., and Vernadakis, A. "Stimulation of Ornithine Decarboxylase Activity In Culture." Trans. Am. Soc. Neurochem. 10: 130, 1979.

Parker, K., Arnold, A., Strong, S., and Vernadakis, A. "Maturational Profile of Ornithine Decarboxylase Activity in Vivo and in Culture." The Pharmacologist 20: 272, 1978.

Parker, K.K., Chan, S.-L., and Trevor, A.J. "Affinity Chromatography of the 14S and 18S Forms of Acetyl-cholinesterase." Trans. Am. Soc. Neurochem. 8: 170, 1977.

Parker, K.K., Chan, S.-L., and Trevor, A.J. "Purification of Acetylcholinesterase from Fresh Electric Organ by Affinity Chromatography." The Pharmacologist 18: 146, 1976.

Reviews:

Parker, K.K. Review of "Nucleic Acid Structure and Synthesis," by J.H.K. Parish. In J. Chem. Ed. 65: A298-299.

Solicited Publications:

Adams, J.D., Lien, E.J., and Parker, K.K. “Extracellular and

Intracellular Signaling-An Introduction.” In Intracellular and Extracellular Signaling. Adams, J.D., and Parker, K.K. (Eds.) Royal Society of Chemistry, Cambridge, Chap. 1, 1-9, 2011.

Parker, K.K. “Involvement of Adipokines in Migraine Headache.” In

Intracellular and Extracellular Signaling. Adams, J.D., and Parker, K.K. (Eds.) Royal Society of Chemistry, Cambridge, Chap.7, 116-129, 2011.

Contributor to: “Glossary for Chemists of Terms Used in Toxicology.” Pure and Applied Chemistry 65 (9): 2003-2122, 1993.

Parker, K.K. “Psychoactive Drug Therapy.” In Magill’s Survey of Social Sciences: Psychology. Salem Press, June 1993, pgs. 1891-1897.

Parker, K.K. “Li Isolates the Human Growth Hormone.” In Great Events from History II: Science and Technology. Salem Press, August 1991, pgs. 1358-1362.

Parker, K.K. "Wilkins Discovers Reserpine, The First Tranquilizer." In Great Events from History II: Science and Technology. Salem Press, August 1991, pgs. 1353-1357.

Parker, K.K. "Wilkins Introduces Reserpine for the Treatment of High Blood Pressure." In Great Events from History II: Science and Technology. Salem Press, Aug.1991, pgs. 1429-1433.

Parker, K.K. “Ochoa Creates Synthetic RNA.” In Great Events from History II: Sci. and Tech. Salem Press, Aug.1991, pgs. 1363-1367.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download